Sight Sciences Reports Second Quarter 2026 Financial Results

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2026, raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2026.

Recent Financial and Business Highlights * Second quarter revenue of $23.4 million, a 20% increase compared to $19.6 million in the second quarter of 2025. * Interventional Glaucoma (IG) revenue of $20.7 million, an 8% increase compared to $19.2 million in the second quarter of 2025. * Record Interventional Dry Eye (IDE) revenue of $2.7 million, a 704% increase compared to $0.3 million in the second quarter of 2025, and a 98% increase compared to $1.4 million in the first quarter of 2026. * Cash and cash equivalents totaled $79.8 million as of June 30, 2026. Cash usage was $5.2 million in the second quarter of 2026, a 28% improvement compared to the same period in the prior year. Cash usage included $3.8 million of non-recurring items in the quarter, including a $5.4 million litigation success fee, partially offset by $1.6 million of tariff refunds received. Excluding these one-time items, cash usage was $1.4 million, down 81% compared to the same period in the prior year. * Added an estimated 4.1 million patient lives in the second quarter of 2026 following publication of fee schedules from certain insurance plans that align with recently updated Medicare pricing for CPT® code 0563T, increasing total IDE patient lives with access to appropriate reimbursement from approximately 10.4 million to 14.5 million(1). * IG coverage expanded with the addition of approximately 25 million commercial covered lives from Aetna® Inc. (Aetna), one of the largest health plans in the United States. Aetna now recognizes certain implant-free glaucoma procedures, including ab interno canaloplasty (e.g., OMNI) and adult goniotomy (e.g., SION) as medically necessary for mild-to-moderate open-angle glaucoma when specified clinical criteria are met. This coverage policy is retroactive to July 14, 2026. * Received U.S. Food and Drug Administration 510(k) clearance of the OMNI® Ultra Surgical System (OMNI Ultra). OMNI Ultra with TruSync™ Plus technology is designed to provide surgeons with improved procedural control, efficiency, and versatility, while maintaining the safety and reliability of the OMNI platform. “We delivered a strong second quarter, with revenue growth accelerating to 20% year-over-year, and both business segments contributing meaningfully to the robust growth. Our performance reflects the growing interventional mindset across glaucoma and dry eye disease, the strength of our market-leading technologies, and the focus of our experienced commercial teams in partnering with customers to make interventional eye care the new standard of care,” said Paul Badawi, Co-Founder and CEO of Sight Sciences. “Interventional Glaucoma revenue grew 8%, marking our fourth consecutive quarter of growth, and Interventional Dry Eye revenue nearly doubled sequentially for the second consecutive quarter and reached record quarterly sales. Importantly, we achieved this growth while maintaining strong gross margins and disciplined operating expense and cash management. Based on our year-to-date performance and business momentum, we are raising our 2026 revenue guidance, reducing our adjusted operating expense guidance, and we believe we are well positioned for the second half of the year.”